Detalhe da pesquisa
1.
Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.
J Biol Chem
; 289(26): 18008-21, 2014 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24821719
2.
Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.
Antimicrob Agents Chemother
; 59(2): 1052-60, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25451052
3.
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
J Med Chem
; 65(7): 5675-5689, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332774
4.
Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical Candidates.
J Med Chem
; 65(24): 16234-16251, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36475645
5.
Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer.
Eur J Med Chem
; 224: 113686, 2021 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34303079
6.
From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9.
Cell Chem Biol
; 27(1): 32-40.e3, 2020 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31653597
7.
Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.
J Mol Biol
; 429(7): 1030-1044, 2017 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28232034
8.
From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9.
Cell Chem Biol
; 28(2): 243, 2021 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33607006
9.
Elucidation of DnaE as the Antibacterial Target of the Natural Product, Nargenicin.
Chem Biol
; 22(10): 1362-73, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26456734
10.
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Cancer Discov
; 3(7): 742-50, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23614898